1.60 % to Target, Canaccord Genuity Reaffirms ‘”Buy”’ Rating on Merit Medical Systems (NASDAQ:MMSI) Shares Today

February 25, 2018 - By Nellie Frank

 1.60 % to Target, Canaccord Genuity Reaffirms ‘

Investors sentiment decreased to 1.28 in 2017 Q3. Its down 0.21, from 1.49 in 2017Q2. It is negative, as 14 investors sold Merit Medical Systems, Inc. shares while 71 reduced holdings. 44 funds opened positions while 65 raised stakes. 44.33 million shares or 0.69% more from 44.02 million shares in 2017Q2 were reported.

Dalton Greiner Hartman Maher & accumulated 493,019 shares. Employees Retirement System Of Texas holds 13,000 shares. 1492 Capital Mgmt Llc stated it has 1.04% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI). Art Advsr Ltd Limited Liability Company holds 0.05% or 24,400 shares in its portfolio. Thomson Horstmann Bryant Inc, Connecticut-based fund reported 153,866 shares. Emerald Mutual Fund Advisers Tru reported 0.42% in Merit Medical Systems, Inc. (NASDAQ:MMSI). State Board Of Administration Of Florida Retirement Sys, Florida-based fund reported 41,490 shares. Parkside State Bank And Tru has 27 shares for 0% of their portfolio. Comerica State Bank holds 54,402 shares. Loomis Sayles & L P holds 0.08% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 837,382 shares. Rothschild Asset Management Inc holds 711,321 shares or 0.33% of its portfolio. Bancorp Of Montreal Can holds 87,677 shares. Moreover, Bessemer Group has 0.01% invested in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 38,400 shares. Us Bank De invested in 0.01% or 37,542 shares. Ubs Asset Mngmt Americas has invested 0% in Merit Medical Systems, Inc. (NASDAQ:MMSI).

Since September 11, 2017, it had 0 insider purchases, and 3 sales for $517,063 activity.

Merit Medical Systems (NASDAQ:MMSI) Rating Reaffirmed

Canaccord Genuity now has a $47.5 target price on shares of Merit Medical Systems (NASDAQ:MMSI). The target price gives a potential upside of 1.60 % from the last stock close of Merit Medical Systems (NASDAQ:MMSI). This rating was disclosed to clients in an analyst report on 16 November.

Investors sentiment decreased to 1.28 in 2017 Q3. Its down 0.21, from 1.49 in 2017Q2. It is negative, as 14 investors sold Merit Medical Systems, Inc. shares while 71 reduced holdings. 44 funds opened positions while 65 raised stakes. 44.33 million shares or 0.69% more from 44.02 million shares in 2017Q2 were reported.

Dalton Greiner Hartman Maher & accumulated 493,019 shares. Employees Retirement System Of Texas holds 13,000 shares. 1492 Capital Mgmt Llc stated it has 1.04% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI). Art Advsr Ltd Limited Liability Company holds 0.05% or 24,400 shares in its portfolio. Thomson Horstmann Bryant Inc, Connecticut-based fund reported 153,866 shares. Emerald Mutual Fund Advisers Tru reported 0.42% in Merit Medical Systems, Inc. (NASDAQ:MMSI). State Board Of Administration Of Florida Retirement Sys, Florida-based fund reported 41,490 shares. Parkside State Bank And Tru has 27 shares for 0% of their portfolio. Comerica State Bank holds 54,402 shares. Loomis Sayles & L P holds 0.08% of its portfolio in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 837,382 shares. Rothschild Asset Management Inc holds 711,321 shares or 0.33% of its portfolio. Bancorp Of Montreal Can holds 87,677 shares. Moreover, Bessemer Group has 0.01% invested in Merit Medical Systems, Inc. (NASDAQ:MMSI) for 38,400 shares. Us Bank De invested in 0.01% or 37,542 shares. Ubs Asset Mngmt Americas has invested 0% in Merit Medical Systems, Inc. (NASDAQ:MMSI).

Since September 11, 2017, it had 0 insider purchases, and 3 sales for $517,063 activity.

Merit Medical Systems, Inc. (NASDAQ:MMSI) Ratings Coverage

Among 8 analysts covering Merit Medical (NASDAQ:MMSI), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Merit Medical has $51.0 highest and $22 lowest target. $44’s average target is -5.88% below currents $46.75 stock price. Merit Medical had 18 analyst reports since October 23, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Raymond James on Monday, August 28. Wells Fargo maintained Merit Medical Systems, Inc. (NASDAQ:MMSI) rating on Thursday, November 30. Wells Fargo has “Buy” rating and $51.0 target. Barrington Research upgraded the shares of MMSI in report on Monday, October 26 to “Outperform” rating. Canaccord Genuity maintained Merit Medical Systems, Inc. (NASDAQ:MMSI) on Sunday, October 8 with “Buy” rating. The firm has “Buy” rating given on Monday, September 4 by Canaccord Genuity. SunTrust maintained the shares of MMSI in report on Thursday, November 16 with “Buy” rating. The firm has “Buy” rating given on Thursday, October 26 by Canaccord Genuity. The rating was initiated by Bank of America on Thursday, July 20 with “Buy”. The firm has “Buy” rating by Canaccord Genuity given on Thursday, July 27. Canaccord Genuity initiated the shares of MMSI in report on Tuesday, July 19 with “Buy” rating.

The stock increased 2.30% or $1.05 during the last trading session, reaching $46.75. About 123,845 shares traded. Merit Medical Systems, Inc. (NASDAQ:MMSI) has risen 81.84% since February 25, 2017 and is uptrending. It has outperformed by 65.14% the S&P500.

Analysts await Merit Medical Systems, Inc. (NASDAQ:MMSI) to report earnings on February, 28 after the close. They expect $0.32 EPS, up 3.23 % or $0.01 from last year’s $0.31 per share. MMSI’s profit will be $16.07 million for 36.52 P/E if the $0.32 EPS becomes a reality. After $0.32 actual EPS reported by Merit Medical Systems, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Merit Medical Systems, Inc. designs, develops, makes, and markets medical products for interventional and diagnostic procedures worldwide. The company has market cap of $2.35 billion. The company??s Cardiovascular segment offers cardiology and radiology devices for diagnosing and treating coronary arterial, peripheral vascular, and other non-vascular diseases; and embolotherapeutic products. It has a 79.64 P/E ratio. It also provides vascular access products; guide wires, inflation devices, and diagnostic catheters for use in angiography procedures; therapeutic infusion systems and safety products; drainage catheters and drainage access products, support catheters, vascular retrieval devices, and dialysis access products; and embosphere microspheres and delivery systems, and microcatheters.

More recent Merit Medical Systems, Inc. (NASDAQ:MMSI) news were published by: Globenewswire.com which released: “Merit Medical Closes Deal With BD for Purchase of Divestment Assets” on February 15, 2018. Also Globenewswire.com published the news titled: “Merit Medical to Participate at Six Conferences” on February 22, 2018. Globenewswire.com‘s news article titled: “Merit Medical Systems to Announce Fourth Quarter and Year End Results on …” with publication date: February 12, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.